drugset
drugset / Trial / NCT02960945

Open-Label Crossover Study Comparing CTP-543 to Jakafi®

NCT02960945 ↗

Phase 1 Completed 12 enrolled Concert Pharmaceuticals
RandomizedCrossoverOpen-labelBasic science

Summary

This study will assess the metabolite and pharmacokinetic (PK) profile of a single dose of CTP-543 compared to a single dose of Jakafi® in healthy volunteers.

Timeline

Start
2016-11
Primary completion
2017-01
Completion
2017-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 16 mg Oral
Comparator Ruxolitinib Small molecule 15 mg Oral

Indications

No indication recorded.